KRAS Mutation as Predictor Factor in Locally Advanced Rectal Cancer
Corresponding AuthorFernando Arias
Radiation Oncology Service, Complejo Hospitalario de Navarra, Pamplona, Spain
A B S T R A C T
Introduction: Standard treatment of locally advanced rectal cancer (LARC) includes neoadjuvant chemoradiotherapy followed by total mesorectal excision (TME). The role of KRAS as a biomarker in rectal cancer remains equivocal. We evaluate the Tumor Regression Grade (TRG), Relapse-Free Survival (RFS) and Overall Survival (OS) according to the KRAS oncogene status in LARC Material and Method: We evaluated the KRAS status in 23 patients with LARC. Tumor DNA was obtained from pretreatment biopsy tissues. Results: KRAS mutation was found in 30,4% of the patients. TRG (1-2) after CRT were 56,2% and 42,8%, for wild-type and mutant KRAS groups (p= NS). After a median follow-up of 31 months, there was no difference in RFS (47,7 vs 23,3 months) or OS (51,5 vs 30 months) between wild-type and mutant-type KRAS groups, respectively. Conclusions: Although KRAS status seems to have slightly better prognosis in LARC, it does not reach significant results (probably due to insufficient sample) in TRG, RFS or OS.
Article TypeResearch Article
Publication historyReceived: Tue 30, Jul 2019
Accepted: Tue 13, Aug 2019
Published: Sat 24, Aug 2019
Copyright© 2023 Fernando Arias. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.